VCAM Specific Neutra™ Antibody Products

Are you struggling with inconsistent outcomes in inflammatory disease models or delays in validating therapeutic candidates? Creative Biolabs' VCAM-specific Neutra™ antibodies leverage advanced epitope mapping and affinity maturation technologies to accelerate drug discovery by enabling precise targeting of VCAM-1, a critical mediator of chronic inflammation and immune dysregulation.

Introduction to VCAM

Vascular Cell Adhesion Molecule-1 (VCAM), also designated as CD106, is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is constitutively expressed at low levels on endothelial cells but undergoes rapid upregulation under inflammatory stimuli such as TNF-α, IL-1β, or oxidative stress. VCAM mediates leukocyte adhesion and transmigration during inflammation by binding to α4β1 integrin (VLA-4) on immune cells, making it a linchpin in chronic inflammatory and autoimmune pathologies.

• Structure

VCAM comprises seven extracellular immunoglobulin-like domains (D1–D7), a single transmembrane helix, and a short cytoplasmic tail. The ligand-binding interface localizes to domains D1 and D4, with D1 primarily interacting with α4β1 integrin. Structural studies reveal that conformational flexibility in D1 allows dynamic engagement with VLA-4, while domain clustering on endothelial surfaces enhances avidity for leukocyte recruitment.

• Related Signaling Pathways

VCAM-α4β1 binding activates intracellular signaling cascades in both endothelial and leukocyte populations:

- NF-κB Pathway: Sustained VCAM expression in endothelial cells is regulated via NF-κB, perpetuating inflammation.

- PI3K/Akt Pathway: Leukocyte adhesion triggers PI3K-dependent cytoskeletal rearrangements, facilitating transmigration.

- MAPK Pathway: VCAM engagement amplifies pro-inflammatory cytokine secretion in monocytes, reinforcing immune activation.

Fig.1 Signal transduction pathway of VCAM-1 during inflammatory responses.¹

• Related Diseases

VCAM overexpression is implicated in atherosclerosis, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. In atherosclerosis, VCAM-rich endothelial surfaces recruit monocytes into subendothelial spaces, driving plaque formation. Similarly, in rheumatoid arthritis, synovial VCAM upregulation fosters leukocyte infiltration, exacerbating joint destruction.

Applications of Anti-VCAM Neutralizing Antibodies

• Therapeutic Development for Chronic Inflammation

Anti-VCAM antibodies are being evaluated in Phase II trials for Crohn's disease and psoriasis. By blocking leukocyte extravasation, they reduce tissue damage and inflammatory cytokine storms. A recent trial showed a 40% reduction in disease flares in patients receiving anti-VCAM therapy compared to placebo.

• Diagnostic and Prognostic Biomarker Detection

Quantitative ELISA kits using anti-VCAM antibodies detect soluble VCAM (sVCAM) in serum, serving as a biomarker for endothelial dysfunction. Elevated sVCAM levels predict cardiovascular event risk in diabetic patients, guiding early intervention strategies.

• Mechanistic Studies in Autoimmunity

Researchers employ these antibodies to dissect VCAM's role in tertiary lymphoid structure formation. In multiple sclerosis models, antibody-mediated VCAM inhibition disrupts lymphocyte migration across the blood-brain barrier, attenuating demyelination.

Our Anti-VCAM Antibodies

Neutralizing antibodies targeting VCAM inhibit pathological leukocyte adhesion without compromising basal immune surveillance. Key attributes include:

- High Specificity: Engineered paratopes selectively bind the D1 domain, blocking α4β1 interaction.

- Dual Functional Moieties: Some antibodies incorporate Fc engineering to extend serum half-life or enhance effector functions.

- Preclinical Validation: Demonstrated efficacy in reducing leukocyte infiltration in murine models of colitis and atherosclerosis. These antibodies enable quantitative assessment of soluble VCAM levels in patient sera, correlating with disease activity and therapeutic response.

Creative Biolabs offers VCAM-specific Neutra™ antibodies with unmatched precision for researchers and developers tackling inflammation-driven diseases. With rigorously validated specificity and customizable formats for ELISA, flow cytometry, and in vivo studies, these tools empower breakthroughs in therapeutic and diagnostic research innovation.

Contact our team today to explore how our antibody solutions can advance your projects.

REFERENCE

1. Kong, Deok-Hoon, et al. "Emerging roles of vascular cell adhesion molecule-1 (VCAM-1) in immunological disorders and cancer." International journal of molecular sciences 19.4 (2018): 1057. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms19041057